Anavex Life Sciences (AVXL) to Release Earnings on Monday

Anavex Life Sciences (NASDAQ:AVXL) is expected to be releasing its Q1 2026 results before the market opens on Monday, February 9th. Analysts expect Anavex Life Sciences to post earnings of ($0.10) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, February 9, 2026 at 8:30 AM ET.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Tuesday, November 25th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. During the same period in the previous year, the business posted ($0.14) earnings per share. On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Trading Up 7.6%

Shares of AVXL stock opened at $4.10 on Friday. The company has a market cap of $366.34 million, a price-to-earnings ratio of -7.59 and a beta of 1.21. The stock has a 50 day simple moving average of $4.28 and a 200-day simple moving average of $7.16. Anavex Life Sciences has a 12-month low of $2.86 and a 12-month high of $13.99.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on AVXL shares. Jones Trading cut Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. D. Boral Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Anavex Life Sciences in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anavex Life Sciences in a research note on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Anavex Life Sciences in a report on Friday, December 19th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Anavex Life Sciences currently has an average rating of “Hold” and a consensus target price of $22.00.

Institutional Trading of Anavex Life Sciences

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new stake in Anavex Life Sciences during the 3rd quarter worth about $727,000. Verition Fund Management LLC grew its holdings in shares of Anavex Life Sciences by 109.8% during the third quarter. Verition Fund Management LLC now owns 68,859 shares of the biotechnology company’s stock worth $613,000 after buying an additional 36,039 shares in the last quarter. Quarry LP purchased a new stake in shares of Anavex Life Sciences during the third quarter worth about $36,000. Brevan Howard Capital Management LP acquired a new position in shares of Anavex Life Sciences in the third quarter valued at approximately $153,000. Finally, Bank of America Corp DE lifted its stake in shares of Anavex Life Sciences by 3.7% during the third quarter. Bank of America Corp DE now owns 170,886 shares of the biotechnology company’s stock valued at $1,521,000 after buying an additional 6,157 shares during the period. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.